GlaxoSmithKline is seeking permission to market its asthma biologic mepolizumab for the treatment of eosinophilic chronic obstructive pulmonary disease (COPD) in the US.
News
Overseas recruitment essential to NHS, say trust chiefs
Any significant cut in the number of overseas staff working in the NHS in the next few years is likely to have a “serious and damaging impact” on services, NHS Providers is warning.
No-deal Brexit could create meds supply chaos, warns report
In the event that the UK fails to reach a deal for Brexit there would be “substantial problems” for the NHS, warns a new analysis by independent think tank The Nuffield Trust.
Bayer files low-dose Xarelto/aspirin combo
Bayer is seeking permission to market in Europe its bloodthinner Xarelto in combination with aspirin to reduce the risk of cardiovascular events in patients with coronary or peripheral artery disease.
Roche’s Alecensa wins wider US approval for lung cancer
Roche group Genentech says its application to expand the use of Alecensa to include first-line treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) has been approved by US regulators.
New test could detect oesophageal cancer years earlier
Scientists have developed a new genetic test that they believe could help diagnose oesophageal cancer up to eight years before symptoms appear in people at a high risk of the disease.
NHS offers virtual GP consultations
The NHS has become the first health service in the world to provide free, 24/7 healthcare via mobile phone following the launch of a new digital service offering virtual GP consultations.
Novartis’ Cosentyx shown to inhibit joint damage in PsA
Novartis has presented new data showing that its biologic Cosentyx reduced signs and symptoms of psoriatic arthritis (PsA) while inhibiting progression of joint structural damage.
Speedy review for Jazz’ high-risk AML chemo
Dublin, Ireland-based Jazz Pharmaceuticals’ Vyxeos is being given a speedy review in Europe as a treatment for certain types of high-risk acute myeloid leukemia (AML).
GSK’s R&D chief to leave for UK gov role?
GlaxoSmithKline’s head of R&D Patrick Vallance is reportedly leaving the firm to take on the role of chief scientific advisor at the government.
Novartis files CAR-T therapy in Europe
Novartis has submitted an application to the European Medicines Agency for its CAR-T therapy CTL019 for two haematological indications.
Merck, Pfizer launch Bavencio for rare skin cancer
Merck and Pfizer have launched in the UK of Bavencio, the first medicine to be licensed for the treatment of the rare, aggressive skin cancer of metastatic Merkel Cell Carcinoma (mMCC).
Clive Myrie to interview special guest at Marketer & Communications Team of the Year Awards
Renowned journalist and news anchor Clive Myrie is to interview Chloe Brown, a project worker at Investing in Children (IiC) CiC live on stage at next week’s PharmaTimes Marketer & Communications Team of the Year Awards.
Government unveils plans to accelerate access to medicine
The government has finally published its long-awaited response to the Accelerated Access Review, with plans for a new Accelerated Access Pathway that will open a new channel providing patients with faster access to the most innovative medicines and technologies.
Novartis, Amgen, BAI start new Alzheimer’s prevention study
Novartis, Amgen and the Banner Alzheimer’s Institute (BAI) have expanded their collaboration to initiate a new study investigating BACE1 inhibitor CNP520 can prevent or delay the onset of Alzheimer’s disease symptoms in a high-risk population.
